Business
Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia
Gastrointestinal Stromal Tumors Cells Rapidly Died Between 48 and 72 Hours After Exposure to HT-KIT. HT-KIT Shows Positive Results in AML Positive Preclinical
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"Gastrointestinal Stromal Tumors Cells Rapidly Died Between 48 and 72 Hours After Exposure to HT-KIT.\nHT-KIT Shows Positive Results in AML\nPositive Preclinical Results of Novel HT-KIT Therapeutic Performed at NC State University\nNEW YORK, Sept. 13, 2023 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that HT-KIT, a new molecular entity, for the treatment of advance systemic mastocytosis (AdvSM) achieved positive preclinical results in a study sponsored by Hoth. HT-KIT is an antisense oligonucleotide that targets the proto-oncogene cKIT by inducing mRNA frame shifting and already has Orphan Drug Designation from the FDA.\n\n \n \n \n \n \n \n\n \nThe sponsored preclinical research was conducted at NC State University (\"NCSU\") over the past two years. The aim of the initial studies was to assess how long HT-KIT was functional in cancerous and non-cancerous mast cells, and to determine whether the cells could develop resistance to HT-KIT. Key findings from initial studies in the mouse model show:\nHT-KIT effectively kills human mast cells that rely on signaling through the KIT receptor to survive.The effects of a single dose of HT-KIT lasted for about 2 weeks.HT-KIT efficacy at reducing KIT expression lasted for 7 daysAdditional studies were then performed to assess whether HT-KIT had potential applications further to the mastocytosis indication. Gastrointestinal stromal tumors (GISTs) are also associated with activating KIT mutations. Key findings from these studies show:\nHT-KIT potently reduced KIT expression using GIST cells and that GIST cells rapidly died between 48 and 72 hours after exposure to HT-KIT.Further, we also examined the effects of HT-KIT on a cell line that represents acute myeloid leukemia (AML) cells, and found KIT expression was lower in the AML cells compared to either the mastocytosis or GIST cells, but was effectively and dose-dependently reduced with HT-KIT treatment over 72 hours.Overall, these data provide strong support for potential applications of HT-KIT outside of mastocytosis and mast cell leukemia where KIT may be expressed and could play a role in disease aggression. Further in vivo and mechanistic studies are underway at NCSU in these diseases.\n\"The results from our HT-KIT preclinical trial further reinforces our belief th...